Drug Trial Radar · NCT03999437
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Last checked: Nov 19, 2026Latest source record: Jun 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
42
Planned (sponsor's estimate)
Start
Jan 2, 2019
Primary completion
Dec 13, 2019
Study completion Jan 3, 2020
Sponsor
- Lead sponsor
- United LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton interdigitale (formerly Trichophyton mentagrophytes), and Epidermophyton floccosum. Diagnosis of tinea pedia involves clinical symptoms as well as microscopic examination. Topical therapies are usually applied once or twice daily for as long as 4 weeks, posing a challenge to compliance. The current study aims to test a formulation of the single-dose 1% terbinafine hydrochloride, as well as a single-dose 1% butenafine hydrochloride, versus a vehicle control in adult Filipino patients with athlete's foot. This study will benefit the Filipino community by helping us determine which anti-fungal cream is most effective for athlete's foot.
Conditions
- Tinea Pedis
Interventions
TERBINAFINE HYDROCHLORIDE (1%)Drug
Topical liquid solution
BUTENAFINE HYDROCHLORIDE (1%)Drug
Topical liquid solution
Vehicle ControlDrug
Topical liquid solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with effective treatment at week 6Time frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Management and Testing Associates, Inc.
City of Muntinlupa, Philippines · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.